



Formulation, Optimization and Evaluation of Immediate Release Tablet of Apixaban

M. S. Gambhire¹, K. N. Gujar¹, A. A. Vaidhya^{2*}

Department of Pharmaceutics, Sinhgad College of Pharmacy, Vadgaon (Bk.), Pune-411041, Maharashtra, India

Abstract: Apixaban is an anticoagulant drug used for the treatment of venous thromboembolic events. It is taken by mouth. It is a direct factor Xa inhibitor. Apixaban has a half-life of 9-14 hours. In atrial fibrillation, the initial dose is 5 mg once daily. Apixaban is poorly soluble in water; hence, the basic objective of this study was to produce immediate release apixaban tablets containing superdisintegrants via direct compression, to improve disintegration, dissolution, and to get a faster onset of action. Superdisintegrants used in this formulation are microcrystalline cellulose and cross-carmellose sodium, sodium starch glycolate. The drug-excipients interaction was investigated by FT-IR. Tablets were subjected to physicochemical characterization such as thickness, weight uniformity, drug content, *in vitro* drug release, and stability studies. Tablets were found to be satisfactory when evaluated for thickness, weight uniformity, *in vitro* drug release, drug content, and disintegration time. The *in vitro* drug release for the optimized formulation N₅ was found to be 96% in 2.45 min. The optimized formulation N₅ (8% CCS) also showed satisfactory drug content (99.68%) and satisfactory stability. The optimized formulation N₅ is further selected and compared with the *in vitro* release profile of the innovator product.

Keywords: Apixaban, venous thromboembolic events, superdisintegrants, Cross-carmellose sodium.